Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis
Abstract Psychosis is the most common neuropsychiatric side-effect of dopaminergic therapy in Parkinson’s disease (PD). It is still unknown which factors determine individual proneness to psychotic symptoms. Schizotypy is a multifaceted personality trait related to psychosis-proneness and dopaminerg...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-020-80765-5 |
| _version_ | 1818716696173608960 |
|---|---|
| author | Carina R. Oehrn Jana Schönenkorb Lars Timmermann Igor Nenadić Immo Weber Phillip Grant |
| author_facet | Carina R. Oehrn Jana Schönenkorb Lars Timmermann Igor Nenadić Immo Weber Phillip Grant |
| author_sort | Carina R. Oehrn |
| collection | DOAJ |
| description | Abstract Psychosis is the most common neuropsychiatric side-effect of dopaminergic therapy in Parkinson’s disease (PD). It is still unknown which factors determine individual proneness to psychotic symptoms. Schizotypy is a multifaceted personality trait related to psychosis-proneness and dopaminergic neurotransmission in healthy subjects. We investigated whether (1) PD patients exhibit lower schizotypy than controls and (2) dopamine-related neuropsychiatric side-effects can be predicted by higher schizotypy. In this cross-sectional study, we used the Oxford-Liverpool Inventory of Feelings and Experiences in 56 PD patients (12 women, mean ± sd age: 61 ± 11 years) receiving their usual dopaminergic medication and 32 age-matched healthy controls (n = 32; 18 women, mean ± sd age: 57 ± 6 years). We further compared schizotypy scores of patients with (n = 18, 32.1%) and without previously experienced psychosis. We found that patients exhibited lower schizotypy than controls. Further, patients with a history of psychosis exhibited higher schizotypy than patients without these symptoms. Using an information theoretic measure and a machine learning approach, we show that schizotypy yields the greatest predictive value for dopamine-associated hallucinations compared to other patient characteristics and disease related factors. Our results indicate an overlap between neural networks associated with schizotypy and the pathophysiology of PD and a relationship between schizotypy and psychotic side-effects of dopaminergic medication. |
| first_indexed | 2024-12-17T19:23:21Z |
| format | Article |
| id | doaj.art-5e331ba6e11a40ac8c2f3610f9fdfc66 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-17T19:23:21Z |
| publishDate | 2021-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-5e331ba6e11a40ac8c2f3610f9fdfc662022-12-21T21:35:26ZengNature PortfolioScientific Reports2045-23222021-01-0111111010.1038/s41598-020-80765-5Schizotypy in Parkinson’s disease predicts dopamine-associated psychosisCarina R. Oehrn0Jana Schönenkorb1Lars Timmermann2Igor Nenadić3Immo Weber4Phillip Grant5Department of Neurology, Philipps-University MarburgDepartment of Neurology, Philipps-University MarburgDepartment of Neurology, Philipps-University MarburgCenter for Mind, Brain and Behavior (CMBB), Philipps-University MarburgDepartment of Neurology, Philipps-University MarburgPsychology School, Fresenius University of Applied SciencesAbstract Psychosis is the most common neuropsychiatric side-effect of dopaminergic therapy in Parkinson’s disease (PD). It is still unknown which factors determine individual proneness to psychotic symptoms. Schizotypy is a multifaceted personality trait related to psychosis-proneness and dopaminergic neurotransmission in healthy subjects. We investigated whether (1) PD patients exhibit lower schizotypy than controls and (2) dopamine-related neuropsychiatric side-effects can be predicted by higher schizotypy. In this cross-sectional study, we used the Oxford-Liverpool Inventory of Feelings and Experiences in 56 PD patients (12 women, mean ± sd age: 61 ± 11 years) receiving their usual dopaminergic medication and 32 age-matched healthy controls (n = 32; 18 women, mean ± sd age: 57 ± 6 years). We further compared schizotypy scores of patients with (n = 18, 32.1%) and without previously experienced psychosis. We found that patients exhibited lower schizotypy than controls. Further, patients with a history of psychosis exhibited higher schizotypy than patients without these symptoms. Using an information theoretic measure and a machine learning approach, we show that schizotypy yields the greatest predictive value for dopamine-associated hallucinations compared to other patient characteristics and disease related factors. Our results indicate an overlap between neural networks associated with schizotypy and the pathophysiology of PD and a relationship between schizotypy and psychotic side-effects of dopaminergic medication.https://doi.org/10.1038/s41598-020-80765-5 |
| spellingShingle | Carina R. Oehrn Jana Schönenkorb Lars Timmermann Igor Nenadić Immo Weber Phillip Grant Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis Scientific Reports |
| title | Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis |
| title_full | Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis |
| title_fullStr | Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis |
| title_full_unstemmed | Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis |
| title_short | Schizotypy in Parkinson’s disease predicts dopamine-associated psychosis |
| title_sort | schizotypy in parkinson s disease predicts dopamine associated psychosis |
| url | https://doi.org/10.1038/s41598-020-80765-5 |
| work_keys_str_mv | AT carinaroehrn schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis AT janaschonenkorb schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis AT larstimmermann schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis AT igornenadic schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis AT immoweber schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis AT phillipgrant schizotypyinparkinsonsdiseasepredictsdopamineassociatedpsychosis |